Acute Myocardial Infarction in Iceland, is There a Gender Difference in Treatment and Survival?
NCT ID: NCT04544384
Last Updated: 2020-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3257 participants
OBSERVATIONAL
2008-01-01
2020-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sex Differences in Relative Survival and Excess Mortality Following Acute Myocardial Infarction
NCT02952417
MI Mortality Risk and Between-hospital Risk Variation in the United Kingdom and Sweden
NCT01359033
A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis
NCT01984307
Myocardial Infarction With Non-obstructive Coronary Arteries in Turkish Population
NCT03364387
Gender Differences in the Development, Treatment and Prognosis of Coronary Disease: A CALIBER Study
NCT01164371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Information about patient demographics, cardiovascular risk factors, comorbidities, angiography results and treatment were obtained from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), a Swedish Web-based database also used in Iceland that prospectively record both patient- and procedure-related factors. All data are registered by the treating physician and nurses at the time of the procedure.
Clinical definitions Cases of acute myocardial were defined as STEMI and NSTEMI, according to the current European Society of Cardiology guidelines, and determined by the attending cardiologist \[18\]. The NSTEMI diagnosis was introduced into the database 2013 and there was also a change in the Troponin analysis used at that time. This is the reason why we chose to have a shorter study period for the NSTEMI patients. We excluded patients that had not significant coronary artery stenoses. Cardiovascular risk factors, including hypertension, diabetes mellitus, smoking status, statin use, body mass index (BMI) and renal function were recorded. Chronic kidney disease (CKD) was staged according to the Kidney Disease Outcome Quality Initiative (KDOQI) classification. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine measurements using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, and CKD was defined as eGFR \< 60 mL/min/1.73 m2 (stage 3-5).
Prior MI, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were recorded as defined in the database. Since these were AMI patients, they were all done urgently but it was also recorded whether they were done acutely as primary PCIs. The results of the coronary angiography were expressed as the number of vessels involved with significant stenoses or left main stem disease based on angiographic results. If PCI was performed, it was recorded whether patients received aspirin (acetylsalicylic acid) or adenosine diphosphate receptor (ADP) inhibitor before or during the procedure. The choice of treatment, medical therapy alone, PCI or CABG, was at the discretion of the attending interventional cardiologist and/or the heart team.
Observed and Expected Survival Data for all-cause mortality were extracted through linkage with Statistics Iceland. Patients were followed up for their vital status after hospitalization, with censoring at the end of follow-up on October 23, 2019. Expected survival was derived from the general population of Iceland matched to observed survival for the study population by sex, age and year of hospitalization.
Statistical analysis All calculations were performed using R software version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). All continuous variables were normally distributed and were compared with Student´s t-test and presented as mean ± standard deviation (SD). Categorical variables were compared using Chi-square test if the observed data was over five, otherwise Fisher´s Exact test was performed. Statistical significance was prespecified at 5% (P \< 0.05) Kaplan-Meier curve was plotted to assess the estimated long-term survival and the two groups were compared using a log-rank test. To identify independent prognostic factors for survival, a Cox multivariate analysis was used, represented as hazard ratios with 95% confidence intervals.
Relative survival was defined as the observed survival among patients with AMI divided by expected survival in populace of Iceland matched by sex, age and year.
As individual patients were not identified, obtaining individual consent for the study was not obtained.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with STEMI during 2008-2018 that underwent coronary angiography
Exclusion Criteria
* Not first presentation of NSTEMI or STEMI during the study period
* Lost survival data
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Statistics Iceland
UNKNOWN
Landspitali University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ingibjorg Gudmundsdottir, Phd, MD
Role: STUDY_DIRECTOR
Landspitali
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LSH-19-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.